Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was effective in a phase 2b trial, although shares in the company ...

With the development of marine, rail and, above all, aviation, the need for precision has continued to grow: trains must ...

Hardly Strictly best bets Salute to Service photo gallery New driver’s license design Local restaurant among continent’s best Outrage over carpool lane hours The Farm Bureau did not share when the ...